Cancer Research The Future of Cancer Research: Science and Patient Impact  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 49, 816-820, February 15, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boyd, D.
Right arrow Articles by Brattain, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boyd, D.
Right arrow Articles by Brattain, M.

Examination of Urokinase Protein/Transcript Levels and Their Relationship with Laminin Degradation in Cultured Colon Carcinoma1

Douglas Boyd, Barry Ziober, Subhas Chakrabarty and Michael Brattain2

Department of Pharmacology, Bristol-Baylor Laboratory, Baylor College of Medicine, Houston, Texas 77030

Conditioned medium derived from the colon cancer cell lines was ineffective in solubilizing immobilized radiolabeled laminin. However, substantial degradation was observed in the presence of plasminogen and could be largely blocked by preincubation with polyclonal anti-urokinase antibody. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the solubilized products generated either by the conditioned medium or by authentic urokinase supplemented with plasminogen yielded identical results. Analysis of the spent medium for urokinase by an enzyme-linked immunosorbent assay method revealed a similar profile to that achieved with the laminin degradation assays for the six cell lines tested. However, Northern analysis of urokinase-specific mRNA indicated that protein levels could not be entirely predicted by steady-state levels of the transcript.

In a previous study, undifferentiated colon cancer cell lines expressed larger amounts of the plasminogen activator into the conditioned medium compared with their well-differentiated counterparts. However, these earlier studies were performed using cells grown in defined medium which lacked epidermal growth factor (EGF). EGF has been reported to affect plasminogen activator levels. Consequently, to investigate the role of EGF in the modulation of urokinase protein/activity, cell types representative of well- and poorly differentiated colon cancer were examined for their sensitivity of expression to this growth factor. In the absence of EGF, primitive cell types secreted, on average, 5 times more urokinase than their well-differentiated counterparts. In response to EGF, however, well-differentiated cell lines exhibited 4- to 6-fold increases in these parameters while the primitive cell lines were refractory to the peptide. Consequently, the differences in urokinase protein expressed by the well-and poorly differentiated groups of cells were abolished by the presence of EGF.

The expression of a well-differentiated phenotype by colon cancer cell types in vivo probably depends to some extent on laminin within a basement membrane. The data presented herein are consistent with the idea that depletion of this glycoprotein from a basement membrane by urokinase-dependent mechanisms may contribute to the undifferentiated phenotype seen with many of these malignancies.

1 This work was supported by NIH Grant CA34432.

2 To whom requests for reprints should be addressed.

Received 6/28/88. Revised 9/27/88. Accepted 11/11/88.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
D. D. Boyd, H. Wang, H. Avila, N. U. Parikh, H. Kessler, V. Magdolen, and G. E. Gallick
Combination of an Src Kinase Inhibitor with a Novel Pharmacological Antagonist of the Urokinase Receptor Diminishes in Vitro Colon Cancer Invasiveness
Clin. Cancer Res., February 15, 2004; 10(4): 1545 - 1555.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. B. Pustilnik, V. Estrella, J. R. Wiener, M. Mao, A. Eder, M.-A. V. Watt, R. C. Bast Jr., and G. B. Mills
Lysophosphatidic Acid Induces Urokinase Secretion by Ovarian Cancer Cells
Clin. Cancer Res., November 1, 1999; 5(11): 3704 - 3710.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. R. Harvey, S. N. J. Sait, Y. Xu, J. L. Bailey, R. M. Penetrante, and G. Markus
Demonstration of Urokinase Expression in Cancer Cells of Colon Adenocarcinomas by Immunohistochemistry and in Situ Hybridization
Am. J. Pathol., October 1, 1999; 155(4): 1115 - 1120.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Lengyel, H. Wang, E. Stepp, J. Juarez, Y. Wang, W. Doe, C. M. Pfarr, and D. Boyd
Requirement of an Upstream AP-1 Motif for the Constitutive and Phorbol Ester-inducible Expression of the Urokinase-type Plasminogen Activator Receptor Gene
J. Biol. Chem., September 20, 1996; 271(38): 23176 - 23184.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Yan, H. Wang, and D. D. Boyd
KiSS-1 Represses 92-kDa Type IV Collagenase Expression by Down-regulating NF-kappa B Binding to the Promoter as a Consequence of Ikappa Balpha -induced Block of p65/p50 Nuclear Translocation
J. Biol. Chem., January 5, 2001; 276(2): 1164 - 1172.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1989 by the American Association for Cancer Research.